This randomized, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the safety and efficacy of povorcitinib (INCB54707) in adult patients with prurigo nodularis (PN ...

Pillow Talk, one of Australia’s most loved homewares and bedding brands, is excited to announce a new partnership with digital marketing agency Reload Media following a highly competitive tender ...

Exciting times are ahead in the next few years for the prurigo nodularis treatment market as it is projected to grow to $2.11 billion in 2029, marking a compound annual growth rate CAGR of 5.1%.

The pillow itself is incredibly supportive, with a memory foam layer that cradles your neck, and evenly distributes pressure and weight for the optimum quality of sleep. Shoppers say it's the "most ...

Original results from the phase 3 OLYMPIA 1 (NCT04501679) and 2 (NCT04501666) trials demonstrated the safety and efficacy of nemolizumab administered subcutaneously every 4 weeks in 560 patients ...

Galderma’s Nemluvio (nemolizumab) has demonstrated sustained and clinically meaningful improvements in the key signs and symptoms of prurigo nodularis, according to results from a long-term extension ...

Business Wire India An interim analysis of the OLYMPIA long-term extension study to be presented as a late-breaking abstract at the XIV International Congress of Dermatology (ICD) found that Nemluvio ...

Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data show ...

The OLYMPIA long-term extension study was designed to assess the safety and efficacy of Nemluvio in patients with prurigo nodularis up to four years and includes 508 patients from the phase II trial ...

Ständer S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5 (4):e42. doi: 10.1097/itx.0000000000000042 ...